Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats.
Acute lung injury (ALI) is a devastating disease, which is characterized by diffuse endothelium, epithelial damage, and increased pulmonary capillary permeability. Recent data have suggested that the circulating endothelial progenitor cells (EPCs) play an important role in endothelial repair after vascular injury. This study was undertaken to investigate possible endothelial-repairing effects of EPC transplantation after LPS-induced ALI in rats. Using Y-chromosome in situ hybridization and reverse transcription polymerase chain reaction assay, we detected the expression of sex-determining region y in the injured lungs of female model rats, suggesting that allogenic EPCs can migrate to the injured lung tissues. Rats that have received the EPC treatment had a reduced pulmonary edema level, inflammation, hemorrhage, and hyaline membrane formation, as well as an increased survival rate from 44% to 81%. Furthermore, anti-inflammatory cytokine IL-10 levels were dramatically increased in the EPC-treated rats compared with the phosphate buffered saline-treated rats. On the contrary, endothelin-1 and iNOS were downregulated in the EPC-treated group. These findings provide evidence that i.v. EPC treatment results in engraftment of EPCs to the injured lung tissue, which can significantly attenuate lung injury and improve survival in ALI rats. The beneficial effects of EPC engraftment is likely to come from maintaining the integrity of pulmonary alveolar-capillary barrier, reestablishing the endothelial function in vessels and ameliorating the inflammatory state.